GenoSensor Corporation
Private Company
Funding information not available
Overview
Founded in 2015, GenoSensor Corporation has established itself as a provider of genomic technologies and bioassay services, leveraging integrated high-throughput laboratory and microarray fabrication facilities. The company's portfolio includes research tools like microRNA arrays and qPCR kits, as well as diagnostic products, most notably its GS™ COVID-19 RT-PCR Kit which received FDA Emergency Use Authorization. While its core business supports life science research, GenoSensor also markets a blood-based molecular assay, TheraLead™, for clinical applications via a partner, Clinicogen, indicating a move towards predictive and personalized medicine.
Technology Platform
Integrated high-throughput laboratory and microarray fabrication facilities for genomic analysis, specializing in microRNA arrays, qRT-PCR assays, and custom bioassay development.
Opportunities
Risk Factors
Competitive Landscape
Operates in the highly competitive genomics research tools market against large, established players like Thermo Fisher Scientific, Qiagen, and Illumina. In the clinical diagnostics space, it faces competition from major diagnostic companies and numerous startups focused on liquid biopsy and molecular testing.